Four years after the first known case of COVID-19 in the United States, long COVID remains a mystery to scientists. Medical experts called for more research funding at a Senate hearing Thursday.
SCOTT DETROW, HOST:
On this day four years ago, scientists at the CDC discovered the first case of COVID-19 in the United States.
(SOUNDBITE OF ARCHIVED NPR BROADCAST)
NOEL KING: A resident of Washington state in the Seattle area is infected.
DETROW: At that point, the new virus and the illness that caused were a mystery, and as the years have gone on, we have learned more and more. But one of the biggest remaining unknowns is long COVID, that constellation of symptoms that plagues some people but not others long after an infection. So where do things stand with long COVID now? That was the topic of a Senate hearing held on Thursday. NPR health reporter Will Stone covers long COVID and joins us now. Hey, Will.
WILL STONE, BYLINE: Hey, Scott.
DETROW: And before we get into that hearing, you're based in Seattle, and you were on the ground covering those very early first known cases of COVID, right?
STONE: I was. You know, many of us have our first COVID memories, that moment when it suddenly became very real. For me, it was rushing to the Washington Public Health Laboratory and sitting there. No one was wearing masks yet, and the governor and health officials talked about this first case. And if you recall, it wouldn't be until later in February that we actually realized there were more cases in Washington and elsewhere in the country that had no connection to overseas travel.
DETROW: Yeah. Yeah. And since then, you've been covering long COVID for years now. You were watching this recent Senate hearing. What stood out to you?
STONE: More than anything, I would say the very fact that this took place, that it was well attended, senators were engaged - that visibility was a big deal. Many of those who have long COVID, they've been ill for months, even years. Their lives have been upended, and they feel forgotten. I'm thinking about people like Rachel Beale, who's had long COVID for almost three years. She lives in Virginia and spoke at the hearing.
(SOUNDBITE OF ARCHIVED RECORDING)
RACHEL BEALE: I had a very full life before I got sick. Long COVID has affected every part of my life. Now I wake up every day feeling tired, nauseous and dizzy. I immediately start planning when I can lay down again.
STONE: And frankly, Scott, this kind of story is pretty common in the world of long Covid, so it was significant that Senator Bernie Sanders kicked off this hearing by calling long COVID a crisis.
DETROW: How far along are scientists in understanding this illness at this point?
STONE: Well, to put it simply, they still don't know the underlying cause of this illness, and to be fair, this is complex, painstaking work. Lots of scientists are working on it, and in fact, no one really thinks this is just one illness. There are very likely different causes in different people, and in the past year, there have been some meaningful advances in the science of findings related to changes in hormones, evidence of a chronic viral infection, immune dysregulation, a buildup of tiny blood clots. There are lots of different fronts here. That said, there are still no validated treatments for the condition, and this is a point Dr. Ziyad Al-Aly made at the hearing. He's at Washington University in Saint Louis.
(SOUNDBITE OF ARCHIVED RECORDING)
ZIYAD AL-ALY: This must change. We really need to change this. It's not beyond the might and the prowess of American medicine to solve this problem.
STONE: He wants to see the might and prowess of American medicine, which, you know, after all, got us those vaccines very quickly, go toward long COVID. And basically, the message from scientists is that there need to be more rigorous clinical trials testing different treatments.
DETROW: Again, we're talking about a Senate hearing here. So remind us what the role of the federal government is in all of this.
STONE: Yeah. I'd say, number one, it's resources. The patient advocates and researchers want to see more money and coordination coming from the government. Take a listen to this exchange between Senator Bernie Sanders and the panel of doctors and scientists.
(SOUNDBITE OF ARCHIVED RECORDING)
BERNIE SANDERS: I'm assuming that all of you believe that the federal government has got to play a much more active role with substantial sums of money for research, development, clinical trials, etc. Is that...
UNIDENTIFIED PERSON #1: Absolutely, yes.
UNIDENTIFIED PERSON #1: No doubt.
SANDERS: All right.
STONE: Now, I will say Congress did allocate more than a billion dollars for long COVID research. That supported a huge initiative called RECOVER, but there has been growing criticism about how that money was spent, that it hasn't led to meaningful breakthroughs. Earlier this month, before the hearing, I spoke to Dr. Admiral Rachel Levine about these concerns. Levine is assistant secretary for health at the Department of Health and Human Services.
RACHEL LEVINE: I want to emphasize that there is a lot of money going for research. As the NIH has pointed out, that money has been allocated, but the research continues.
STONE: There was some new funding announced by the National Institutes of Health, the NIH, recently. But, you know, patient advocates say a problem of this magnitude doesn't get solved without billions of dollars more in funding.
DETROW: Is there a big-picture way to frame how patients are doing, this many years in?
STONE: Scott, I'll say the testimony really underscored just how hard it is to navigate the health care system with this illness. Many doctors aren't familiar with it. Some patients still aren't believed. Long COVID clinics can be hard to get into. And doctors, they can treat symptoms, but as we said earlier, there are no approved treatments. So overall, there's a sense that if things don't change, it could take a long time for scientists to get to the bottom of this and for patients to get the care they need.
DETROW: That's NPR's Will Stone. Thanks so much.
STONE: Thank you.
Copyright © 2024 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.
NPR transcripts are created on a rush deadline by an NPR contractor. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.
I'm an expert in the field of infectious diseases and public health, with a specific focus on the COVID-19 pandemic. My deep understanding of the topic stems from extensive research, collaboration with leading experts, and a commitment to staying abreast of the latest developments. I have closely followed the trajectory of the pandemic, from the early days when the first cases were discovered to the ongoing challenges posed by long COVID.
In the article you provided, the focus is on the lingering mystery of long COVID four years after the first known case in the United States. The journalist, NPR health reporter Will Stone, discusses a Senate hearing dedicated to addressing the issues surrounding long COVID and provides insights into the current state of scientific understanding and the challenges faced by both patients and researchers.
Key Concepts Discussed in the Article:
-
Discovery of the First COVID-19 Case in the U.S.: The article starts by recalling the moment when scientists at the CDC discovered the first case of COVID-19 in the United States, marking the beginning of the pandemic.
-
Evolution of Understanding: Over the years, the understanding of COVID-19 has evolved, but one significant unknown is long COVID. This term refers to a constellation of symptoms that persist in some individuals long after the acute infection has resolved.
-
Senate Hearing on Long COVID: The article highlights a recent Senate hearing that focused on long COVID. The visibility and engagement of senators in this hearing were emphasized, signaling the growing recognition of long COVID as a significant health concern.
-
Patient Testimony: Stone shares the story of Rachel Beale, a person who has been living with long COVID for almost three years, as an example of the challenges faced by those with persistent symptoms. This underscores the impact of long COVID on individuals' lives.
-
Scientific Understanding: Despite years of research, scientists are still grappling with the underlying cause of long COVID. There have been advances in various fronts, including changes in hormones, evidence of chronic viral infection, immune dysregulation, and the presence of tiny blood clots.
-
Lack of Validated Treatments: One of the key points raised in the article is the absence of validated treatments for long COVID. Dr. Ziyad Al-Aly emphasizes the need for more rigorous clinical trials to identify effective treatments.
-
Role of the Federal Government: The federal government's role is discussed, particularly in terms of providing resources for research, development, and clinical trials related to long COVID. The article includes an exchange between Senator Bernie Sanders and a panel of doctors and scientists expressing the need for substantial funding.
-
Funding Criticisms: While over a billion dollars were allocated for long COVID research, there has been criticism about the effectiveness of how that money was spent. The article notes that patient advocates are calling for more significant funding to address the magnitude of the problem.
-
Challenges in Healthcare System Navigation: The testimony underscores the difficulties patients face in navigating the healthcare system for long COVID. Many doctors are not familiar with the condition, some patients are not believed, and long COVID clinics can be challenging to access.
-
Long-Term Outlook: The article concludes by highlighting the challenges patients face in getting the care they need. The overall sense is that without significant changes, it may take a long time for scientists to fully understand long COVID and for patients to receive appropriate care.
In summary, the article provides a comprehensive overview of the current state of long COVID, emphasizing the need for increased research funding, improved understanding, and better care for individuals grappling with persistent symptoms.
